Abbv-453: A Highly Potent and Selective Next Generation Small Molecule Inhibitor of BCL-2Abbv-453：一种高活性、高选择性的下一代BCL-2小分子抑制剂BLOODIF23.12024-11-050PRE
BCL-XL-targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitorsSCIENCE ADVANCESIF12.52024-10-041OAAI
Enabling, Decagram-Scale Synthesis of Macrocyclic MCL-1 Inhibitor ABBV-467JOURNAL OF ORGANIC CHEMISTRYIF3.62023-11-013PRE
Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patientsCOMMUNICATIONS MEDICINEIF6.32023-10-2520OAAI
Enantioselective Bioreduction of Medicinally Relevant Nitrogen-Heteroaromatic KetonesACS MEDICINAL CHEMISTRY LETTERSIF42023-05-106PRE
Structure-Based Design of A-1293102, a Potent and Selective BCL-XL InhibitorACS MEDICINAL CHEMISTRY LETTERSIF42021-05-1212OAAI
Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL InhibitorACS MEDICINAL CHEMISTRY LETTERSIF42020-03-3093OAAI
Structural basis for the recruitment of glycogen synthase by glycogeninPROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICAIF9.12014-06-3064OAAI
Identification and Preliminary Characterization of a Potent, Safe, and Orally Efficacious Inhibitor of Acyl-CoA:Diacylglycerol Acyltransferase 1JOURNAL OF MEDICINAL CHEMISTRYIF6.82012-02-1035PREAI
Process Development of a Diacyl Glycerolacyltransferase-1 InhibitorORGANIC PROCESS RESEARCH & DEVELOPMENTIF3.52010-02-1515PREAI
Inhibitors of diacylglycerol acyltransferase: a review of 2008 patentsEXPERT OPINION ON THERAPEUTIC PATENTSIF4.62009-12-2030PREAI
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitorJOURNAL OF MEDICINAL CHEMISTRYIF6.82008-01-10146PREAI
Concise construction of novel bridged bicyclic lactams by sequenced Ugi/RCM/Heck reactionsORGANIC LETTERSIF52007-11-0193PREAI
Discovery of ((4R,5S)-5-amino-4-(2,4,5-trifluorophenyl)cyclohex-1-enyl)-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetesJOURNAL OF MEDICINAL CHEMISTRYIF6.82006-10-0759PREAI
Optimization of chromone-2-carboxamide melanin concentrating hormone receptor 1 antagonists: Assessment of potency, efficacy, and cardiovascular safetyJOURNAL OF MEDICINAL CHEMISTRYIF6.82006-09-2951PREAI
Screening for cardiovascular safety: A structure-activity approach for guiding lead selection of melanin concentrating hormone receptor 1 antagonistsJOURNAL OF MEDICINAL CHEMISTRYIF6.82006-03-1145PREAI
Discovery and characterization of aminopiperidinecoumarin melanin concentrating hormone receptor 1 antagonistsJOURNAL OF MEDICINAL CHEMISTRYIF6.82005-08-1958PREAI
Cascade iminium ion reactions for the facile synthesis of quinolizidines.: Concise syntheses of (±)-epilupinine and (-)-epimyrtineORGANIC LETTERSIF52005-04-0947PREAI
Identification of 2-(4-benzyloxyphenyl)-N-[1-(2-pyrrolidin-1-yl-ethyl)-1H-indazol-6-yl]acetamide, an orally efficacious melanin-concentrating hormone receptor 1 antagonist for the treatment of obesityJOURNAL OF MEDICINAL CHEMISTRYIF6.82005-02-15104PREAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项